Top

Published in:

01-09-2015 | Case Report

Successful Treatment Toward Gastrointestinal Stromal Tumors with Aggressive Behavior

Authors: Landolsi Sana, Mannai Saber

Published in: Journal of Gastrointestinal Cancer | Issue 3/2015

Excerpt

Gastrointestinal stromal tumors are rare [1‐3]. Their treatment is still challenging especially for those with aggressive behavior. We herein report two cases of successful treatment toward gastrointestinal stromal tumors having aggressive behavior. …

Furihata M, Fujimori T, Imura J, et al. Malignant stromal tumor, so called “gastrointestinal stromal tumor”, with rhabdomyomatous differentiation occurring in the gallbladder. Pathol Res Pract. 2005;201:609–13. doi:10.1016/j.prp.2005.04.011.PubMedCrossRef

Krska Z, Peskova M, Povysil C, Horejs J, Sedlackova E, Kudrnova Z. GIST of pancreas. Prague Med Rep. 2005;106:201–8.PubMed

Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol. 2000;13:577–85.PubMedCrossRef

Casali PG, Blay JY. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v98–102. doi:10.1093/annonc/mdq208.PubMedCrossRef

Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8 Suppl 2:S1–41. quiz S42–4.PubMedCentralPubMed

Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–104. doi:10.1016/S0140-6736(09)60500-6.PubMedCentralPubMedCrossRef

Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99:42–7. doi:10.1002/jso.21160.PubMedCentralPubMedCrossRef

Fiore M, Palassini E, Fumagalli E, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol. 2009;35:739–45. doi:10.1016/j.ejso.2008.11.005.PubMedCrossRef

Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg. 2007;245:341–6.PubMedCentralPubMedCrossRef

10.

Chaudhry UI, DeMatteo RP. Advances in the surgical management of gastrointestinal stromal tumor. Adv Surg. 2011;45:197–209.PubMedCentralPubMedCrossRef

11.

Sepe PS, Moparty B, Pitman MB, Saltzman JR, Brugge WR. EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield. Gastrointest Endosc. 2009;70(2):254–61. doi:10.1016/j.gie.2008.11.038.PubMedCrossRef

12.

Kalkmanna J, Zeileb M, Antochc G, et al. Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group. Cancer Imaging. 2012;12:126–35. doi:10.1102/1470-7330.2012.0013.CrossRef

13.

Hara M, Takayama S, Arakawa A, Sato M, Nagasaki T, Takeyama H. Transvaginal resection of a rectal gastrointestinal stromal tumor. Surg Today. 2012;42:909–12. doi:10.1007/s00595-012-0215-8.PubMedCrossRef

14.

Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg. 1992;215(1):68–77.PubMedCentralPubMedCrossRef

15.

Hohenberger P, Ronellenfitsch U, Oladeji O, et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg. 2010;97(12):1854–9. doi:10.1002/bjs.7222.PubMedCrossRef

16.

Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70–83.PubMedCrossRef

17.

Von Mehren M, Lor Randall R, Robert SB, et al. Soft tissue sarcoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12:473–83.

18.

The ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Supplement 3):iii21–6. doi:10.1093/annonc/mdu255.CrossRef

19.

Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006;24:2325–31.PubMedCrossRef

20.

Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol. 2012;19:1074–80. doi:10.1245/s10434-011-2190-5.PubMedCentralPubMedCrossRef

21.

Mussi C, Ronellenfitsch U, Jakob J, et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol. 2010;21:403–8. doi:10.1093/annonc/mdp310.PubMedCrossRef

Title: Successful Treatment Toward Gastrointestinal Stromal Tumors with Aggressive Behavior
Authors: Landolsi Sana
Mannai Saber
Publication date: 01-09-2015
Publisher: Springer US
Published in: Journal of Gastrointestinal Cancer / Issue 3/2015
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-015-9706-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2015

Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis

Sustained Disease Control with TOMOXIRI Regimen in a Patient with Metastatic Pancreatic Adenocarcinoma

Surviving Primary Pancreatic Squamous Cell Carcinoma: A Rare Entity

Two Synchronous Colonic Adenocarcinomas, a Gastric Schwannoma and a Mucinous Neoplasm of the Appendix: a Case Report

A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs

Downregulation of the Genes Involved in Reprogramming (SOX2, c-MYC, miR-302, miR-145, and P21) in Gastric Adenocarcinoma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials